Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Preeclampsia With Severe Features Clear all
Terminated Phase 4 Interventional

Metformin and Esomeprazole in Preterm Pre-eclampsia

NCT06359015
View directory record Official record
Conditions
Preeclampsia Severe, Pre-Eclampsia, Preeclampsia, Preeclampsia Second Trimester, Preeclampsia Complicating Childbirth, Preeclampsia Puerperium, Preterm
Interventions
Metformin, Esomeprazole
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

NCT00158743
View directory record Official record
Conditions
Pre-eclampsia
Interventions
Anti-digoxin antibody (FAB fragment), sodium chloride
Drug · Other
Lead sponsor
BTG International Inc.
Other
Eligibility
Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Mobile, Alabama • Phoenix, Arizona • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational

Continuous Non-invasive Hemodynamic Monitoring in Early-onset Severe Preeclampsia: a Comparison of Echocardiography, Bioreactance, and Finger Cuff Measurements

NCT05299229
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
Echocardiogrpahy and non-invasive monitoring
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 24, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

Complement Regulation to Undo Systemic Harm in Preeclampsia

NCT04725812
View directory record Official record
Conditions
Preeclampsia, Severe Preeclampsia, Eculizumab, HELLP, HELLP Syndrome, HELLP Syndrome Second Trimester, Pregnancy Related, AHUS, PNH, Complement Regulatory Factor Defect, Complement Abnormality, HELLP Syndrome Third Trimester
Interventions
Eculizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 24, 2026, 9:32 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Finger Plethysmography to Predict Fluid Responsiveness in Healthy Pregnancy and Severe Preeclampsia

NCT07430254
View directory record Official record
Conditions
Pre-Eclampsia, Severe, Pregnancy
Interventions
Noninvasive finger plethysmographic cardiac output monitoring, Standard transthoracic echocardiographic assessment
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

Low Doses of Aspirin in the Prevention of Preeclampsia

NCT04070573
View directory record Official record
Conditions
Preeclampsia
Interventions
acetylsalicylic acid
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia

NCT00719654
View directory record Official record
Conditions
Preeclampsia
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Female only
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features

NCT02911701
View directory record Official record
Conditions
Pre-Eclampsia, HELLP Syndrome, Eclampsia
Interventions
Acetaminophen, Ibuprofen
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational

Impedance Cardiographic (ICG) Assessment of Pregnant Women With Severe Hypertension to Assess Impact of Standard Therapy

NCT01248169
View directory record Official record
Conditions
Pregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia), Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe), Pregnancy; Hypertension, Gestational Hypertension, With Albuminuria (Severe Pre-eclampsia)
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 2 Interventional

Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial

NCT03978767
View directory record Official record
Conditions
Preeclampsia Severe, Preeclampsia Postpartum
Interventions
Ibuprofen 600 mg, Ketorolac, Acetaminophen, Oxycodone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Terminated Phase 4 Interventional

Acute Labetalol Use in Preeclampsia

NCT03872336
View directory record Official record
Conditions
Preeclampsia With Severe Features
Interventions
Experimental labetalol dose, Current standard of care
Drug · Other
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational

Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification

NCT03815110
View directory record Official record
Conditions
Preeclampsia and Eclampsia, Preeclampsia Severe, Gestational Hypertension, Chronic Hypertension in Obstetric Context, Superimposed Pre-Eclampsia, Preeclampsia Mild
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Nudge to Drive Transitions of Care

NCT04660032
View directory record Official record
Conditions
Preeclampsia, Preeclampsia Severe, Gestational Hypertension, Hypertensive Disorder of Pregnancy, Superimposed Pre-Eclampsia
Interventions
Nudge
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Sep 24, 2026, 9:32 AM EDT
Active, not recruiting Not applicable Interventional

Preeclampsia Educational Program Study (PrEPS)

NCT06373367
View directory record Official record
Conditions
Preeclampsia, Preeclampsia Severe, Preeclampsia Mild, Preeclampsia Postpartum
Interventions
Illustration based application, Text based application
Other
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period

NCT04236258
View directory record Official record
Conditions
Hypertension in Pregnancy, Preeclampsia Severe, Gestational Hypertension, Postpartum Preeclampsia, Postpartum
Interventions
NIFEdipine ER, Enalapril
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 24, 2026, 9:32 AM EDT
Not yet recruiting Phase 4 Interventional

Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound

NCT07167862
View directory record Official record
Conditions
Preeclampsia, Preeclampsia Postpartum, Preeclampsia Severe or Mild
Interventions
Butterfly iQ3 ultrasound system for determination of postpartum volume status, Oral furosemide, Intravenous furosemide
Diagnostic Test · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational

Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)

NCT05096728
View directory record Official record
Conditions
Preeclampsia With Severe Features
Interventions
Nifedipine XL
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational

Expanded NIPT for Pregnancy Complications

NCT04311749
View directory record Official record
Conditions
Fetal Growth Restriction, Preeclampsia Severe
Interventions
Expanded panel cell free DNA testing (non-invasive prenatal testing), Placental biopsy, Umbilical cord blood
Genetic
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
70 participants
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 24, 2026, 9:32 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia

NCT03008616
View directory record Official record
Conditions
Severe Preeclampsia
Interventions
AMAG-423 (digoxin immune fab), Placebo
Biological · Other
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Mobile, Alabama • Kansas City, Kansas • Louisville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Not yet recruiting Phase 4 Interventional

Biomarkers in Management of Post Partum Preeclampsia

NCT07478055
View directory record Official record
Conditions
Preeclampsia Severe, Preeclampsia Postpartum
Interventions
Magnesium Sulfate
Drug
Lead sponsor
Alexander Harrison
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational

Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers

NCT02808494
View directory record Official record
Conditions
Preeclampsia
Interventions
Not listed
Lead sponsor
Illumina, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Newark, Delaware • Boston, Massachusetts • New Brunswick, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor

NCT04392375
View directory record Official record
Conditions
Preeclampsia Severe
Interventions
Nifedipine 30 MG, Placebos
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 24, 2026, 9:32 AM EDT
Terminated Not applicable Interventional Results available

Non-invasive Versus Invasive Blood Pressure Measurement in the Morbidly Obese Parturient With Severe Preeclampsia

NCT03222414
View directory record Official record
Conditions
Pre-Eclampsia, Morbid Obesity, Parturient, Blood Pressure
Interventions
Non-invasive BP recording with conical Ultracheck Curve BP cuff, Non-invasive BP recording with traditional cylindrical BP cuff, Direct invasive arterial pressure
Device · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Metabolic Acid-base Abnormalities in Pre-eclamptic Women Applying the Stewart-Fencl Approach

NCT02164370
View directory record Official record
Conditions
Mild Pre-eclampsia, Severe Pre-eclampsia
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 24, 2026, 9:32 AM EDT